Peroxisome proliferator-activated receptor agonists modulate heart function in transgenic mice with lipotoxic cardiomyopathy
- PMID: 15671204
- DOI: 10.1124/jpet.104.080259
Peroxisome proliferator-activated receptor agonists modulate heart function in transgenic mice with lipotoxic cardiomyopathy
Abstract
hLpL(GPI) transgenic mice that overexpress human lipoprotein lipase (hLpL) with a glycosylphosphatidylinositol anchor on cardiomyocytes develop lipotoxic cardiomyopathy associated with increased cardiac uptake of plasma lipids. We hypothesized that peroxisome proliferator-activated receptor (PPAR)alpha, PPARgamma, or a PPARalpha/gamma agonist would alter cardiac function by modulating lipid uptake by the heart. hLpL(GPI) mice were administered rosiglitazone (10 mg/kg/day), fenofibrate (100 mg/kg/day), or DRF2655, an alkoxy propanoic acid analog (10 mg/kg/day), for 16 days. Rosiglitazone reduced plasma triglyceride (TG) from 107.63 +/- 6.98 to 77.61 +/- 3.98 mg/dl, whereas fenofibrate had no effect. DRF2655 reduced TG to 33.17 +/- 4.12 mg/dl. Rosiglitazone and DRF2655 decreased heart TG and total cholesterol; fenofibrate had no effect. Molecular markers for cardiac dysfunction, atrial natriuretic factor, brain natriuretic peptide, and tumor necrosis factor-alpha were decreased with rosiglitazone and increased with fenofibrate. Echocardiographic measurements showed reduced fractional shortening and increased left ventricular systolic dimension with fenofibrate. No changes in these parameters were observed with rosiglitazone or DRF2655 treatment. Muscle-specific carnitine palmitoyltransferase-1 and fatty acid transporter protein-1 gene expression were increased with fenofibrate and DRF2655 treatment; no change in expression of these genes was noted with rosiglitazone treatment. Rosiglitazone and DRF2655 reduced TG uptake by the heart, and fenofibrate treatment increased fatty acid uptake. Thus, in a lipotoxic cardiomyopathy mouse model, a PPARgamma agonist reduced cardiac lipid and markers of cardiomyopathy, whereas an agonist of PPARalpha did not improve cardiac lipids and worsened heart function. These changes were paralleled by alterations in heart lipid uptake. Overall, PPAR activators exhibit differential effects in this model of lipotoxic dilated cardiomyopathy.
Similar articles
-
The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy.J Cardiovasc Pharmacol. 2007 Jun;49(6):408-15. doi: 10.1097/FJC.0b013e3180544540. J Cardiovasc Pharmacol. 2007. PMID: 17577106
-
Peroxisome proliferator-activated receptor-alpha,gamma-agonist improves insulin sensitivity and prevents loss of left ventricular function in obese dyslipidemic mice.Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):922-8. doi: 10.1161/01.ATV.0000207318.42066.bb. Epub 2006 Feb 2. Arterioscler Thromb Vasc Biol. 2006. PMID: 16456093
-
Cardiac overexpression of hormone-sensitive lipase inhibits myocardial steatosis and fibrosis in streptozotocin diabetic mice.Am J Physiol Endocrinol Metab. 2008 Jun;294(6):E1109-18. doi: 10.1152/ajpendo.00016.2008. Epub 2008 Apr 15. Am J Physiol Endocrinol Metab. 2008. PMID: 18413675
-
Lipids in the heart: a source of fuel and a source of toxins.Curr Opin Lipidol. 2007 Jun;18(3):277-82. doi: 10.1097/MOL.0b013e32814a57db. Curr Opin Lipidol. 2007. PMID: 17495601 Review.
-
Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.Vascul Pharmacol. 2006 Jul;45(1):19-28. doi: 10.1016/j.vph.2005.11.014. Epub 2006 Jun 16. Vascul Pharmacol. 2006. PMID: 16782410 Review.
Cited by
-
Activation of PPARα by Fenofibrate Attenuates the Effect of Local Heart High Dose Irradiation on the Mouse Cardiac Proteome.Biomedicines. 2021 Dec 6;9(12):1845. doi: 10.3390/biomedicines9121845. Biomedicines. 2021. PMID: 34944662 Free PMC article.
-
Targeting fatty acid metabolism for fibrotic disorders.Arch Pharm Res. 2021 Oct;44(9-10):839-856. doi: 10.1007/s12272-021-01352-4. Epub 2021 Oct 18. Arch Pharm Res. 2021. PMID: 34664210 Review.
-
Differentially expressed genes, lncRNAs, and competing endogenous RNAs in Kawasaki disease.PeerJ. 2021 May 12;9:e11169. doi: 10.7717/peerj.11169. eCollection 2021. PeerJ. 2021. PMID: 34026343 Free PMC article.
-
Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug.Cardiovasc Diabetol. 2021 May 18;20(1):109. doi: 10.1186/s12933-021-01294-7. Cardiovasc Diabetol. 2021. PMID: 34006325 Free PMC article. Review.
-
Anti-Hypertensive Action of Fenofibrate via UCP2 Upregulation Mediated by PPAR Activation in Baroreflex Afferent Pathway.Neurosci Bull. 2019 Feb;35(1):15-24. doi: 10.1007/s12264-018-0271-1. Epub 2018 Sep 1. Neurosci Bull. 2019. PMID: 30173356 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous